| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/06/2004 | EP1414495A1 Anti-microbial targeting chimeric pharmaceutical |
| 05/06/2004 | EP1414494A1 Inhibitors of her3 activity |
| 05/06/2004 | EP1414484A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome |
| 05/06/2004 | EP1414478A2 Inhibition of neurodegeneration |
| 05/06/2004 | EP1414471A2 Therapeutic agents comprising pro-apoptotic proteins |
| 05/06/2004 | EP1414469A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 05/06/2004 | EP1414454A1 Paroxetine glycyrrhizinate |
| 05/06/2004 | EP1414452A1 Novel substituted benzimidazole dosage forms and method of using same |
| 05/06/2004 | EP1414435A1 Crystalline composition containing escitalopram |
| 05/06/2004 | EP1414418A1 Compositions and methods to prevent abuse of opioids |
| 05/06/2004 | EP1414416A2 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 05/06/2004 | EP1414414A1 Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers |
| 05/06/2004 | EP1414413A1 Compositions and methods to prevent abuse of opioids |
| 05/06/2004 | EP1414411A1 Pulmonary formulation comprising silicon particles |
| 05/06/2004 | EP1414410A1 Nanoparticulate formulations of fenofibrate |
| 05/06/2004 | EP1414409A1 Stabilized oral suspension formulation |
| 05/06/2004 | EP1414408A1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| 05/06/2004 | EP1414407A2 Dosage forms comprising particles containing active ingredient for application on the skin or mucous membrane |
| 05/06/2004 | EP1414406A2 A bioactive agent delivering system comprised of microparticules within a biodegradable to improve release profiles |
| 05/06/2004 | EP1414390A1 Nanocapsules containing a steroid for cosmetic compositions |
| 05/06/2004 | EP1414299A2 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 05/06/2004 | EP1261613B1 Gastro-specific prodrugs |
| 05/06/2004 | EP1226438B1 Composite nanospheres and their conjugates with biomolecules |
| 05/06/2004 | EP1194153B1 Taste masked pharmaceutical liquid formulations |
| 05/06/2004 | EP1137409B1 Compositions and methods for amelioration of human female sexual dysfunction |
| 05/06/2004 | EP1123283B1 Thiazole-derivatives |
| 05/06/2004 | EP1105139B1 Ophthalmic solution with tetracycline for topical treatment of dry eye disease |
| 05/06/2004 | EP1094721B1 Coloration with pearly luster pigments in the food and pharmaceutical sectors |
| 05/06/2004 | EP1056443B1 Butorphanol sustained release formulations |
| 05/06/2004 | EP1009390A4 Prolonged anesthesia in joints and body spaces |
| 05/06/2004 | EP0999826B1 Self-emulsifying formulation for lipophilic compounds |
| 05/06/2004 | EP0918542B1 Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes |
| 05/06/2004 | EP0889955B1 Recombinant phages |
| 05/06/2004 | EP0869776B1 Stabilised nanoparticles capable of being filtered under sterile conditions |
| 05/06/2004 | EP0831932B1 Novel targeted compositions for diagnostic and therapeutic use |
| 05/06/2004 | EP0812209B1 Cochleate delivery vehicles for biologically relevant molecules |
| 05/06/2004 | DE10248601A1 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/06/2004 | CA2528776A1 Antifungal formulations |
| 05/06/2004 | CA2505597A1 Agent elevating dendritic cell precursor level in blood |
| 05/06/2004 | CA2503383A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 05/06/2004 | CA2503076A1 Novel injectable depot formulations |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2502453A1 Angiogenesis inducer |
| 05/06/2004 | CA2501560A1 Patch and kit containing delayed-type hypersensitivity inducer |
| 05/06/2004 | CA2500836A1 Metal-containing materials, compositions and methods |
| 05/06/2004 | CA2500090A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 05/06/2004 | CA2498276A1 Depot formulations of arylheterocyclic active agents in the form of a suspension |
| 05/06/2004 | CA2493806A1 Aqueous iron carbohydrate complexes, their production and medicaments containing them |
| 05/05/2004 | CN1494569A Antibacterial and fungicidal polymer dispersions and polymer solutions |
| 05/05/2004 | CN1494553A Modified antibodies and method of use |
| 05/05/2004 | CN1494552A Flt 4 (VEGFR-3) as target for tumor imaging and anti-tumor therapy |
| 05/05/2004 | CN1494431A Stable enzymatic wound debrider |
| 05/05/2004 | CN1494421A Highly flexible transdermal therapeutic system having nicotine as active substance |
| 05/05/2004 | CN1494420A Compounds and compositions for delivering active agents |
| 05/05/2004 | CN1494418A Tablets quickly disintegrating in oral cavity |
| 05/05/2004 | CN1493361A Lipid nano-particle of glyceride behenate and its preparation method |
| 05/05/2004 | CN1493360A Preparation method of magnetic guiding anticancer medicine |
| 05/05/2004 | CN1148351C Compound for curing vascular complication, its preparing method and treating use |
| 05/05/2004 | CN1148227C Therapeutic compound and its application |
| 05/05/2004 | CN1148226C Aqueous risperidone formulations |
| 05/05/2004 | CN1148224C Cyclosporin containing composition and process for preparation |
| 05/05/2004 | CN1148186C Clonidine preparation |
| 05/05/2004 | CN1148181C Use of flavnolignanes for the prepn. of medicaments with antiproliferative activity in uterus, ovary and breast |
| 05/05/2004 | CN1148180C Compounds for treatment of estrogen-dependent illnesses and methods for making and using same |
| 05/05/2004 | CN1148174C Nimesulide gel system for topical use |
| 05/05/2004 | CN1148172C Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 05/05/2004 | CN1148170C Polyaminoacid-based particles for use as active principle vectors, and methods for preparing same |
| 05/05/2004 | CN1148168C Micronised pharmaceutical compositions |
| 05/04/2004 | US6730735 Bonding chitosan to polyoxyethylene glycol; gene therapy |
| 05/04/2004 | US6730699 Water soluble paclitaxel derivatives |
| 05/04/2004 | US6730685 H+,k+-atpase inhibitor in a water free solvent; ready-to-use solution for parenteral administration |
| 05/04/2004 | US6730673 Pharmaceutical solutions of levosimendan |
| 05/04/2004 | US6730664 The side-effects of chemotherapy are suppressed or reduced |
| 05/04/2004 | US6730661 Non-digestible dextrans, hydrolysed (galacto)mannans and/or hydrolysed (gluco)mannans; reduce the uptake of high molecular weight substances, allergens and microorganisms through the intestinal wall |
| 05/04/2004 | US6730660 Peritoneal dialysis solutions with polypeptides |
| 05/04/2004 | US6730334 Multi-arm block copolymers as drug delivery vehicles |
| 05/04/2004 | US6730332 Synergistic aqueous extract from fruits of terminalia chebula, bark of albizia lebbeck, terminalia bellerica and emblica officinalis |
| 05/04/2004 | US6730331 Topically applied creatine containing composition |
| 05/04/2004 | US6730329 Zinc containing compositions for anti-viral use |
| 05/04/2004 | US6730328 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 05/04/2004 | US6730327 Polymer blends that swell in an acidic environment and deswell in a basic environment |
| 05/04/2004 | US6730325 Multiparticulate modified release composition |
| 05/04/2004 | US6730324 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 05/04/2004 | US6730319 Pharmaceutical compositions having depressed melting points |
| 05/04/2004 | US6730315 Medium and matrix for long-term proliferation of cells |
| 05/04/2004 | US6730313 Adheres to injury site; releases bioactive agent that reduces or prevents further damage |
| 05/04/2004 | US6730302 Intracellular targeted delivery of compounds by 70 kD heat shock protein |
| 05/04/2004 | US6730293 Compositions and methods for treating inflammatory diseases of the skin |
| 05/04/2004 | US6730288 Lower level of occlusive agent; greater drug skin penetration |
| 05/04/2004 | CA2080226C Cd4-gamma2 and cd4-igg2 chimeras |
| 04/30/2004 | WO2004039294A1 Heat generating article |
| 04/30/2004 | CA2435262A1 Heat-generating body |
| 04/29/2004 | WO2004035794A1 Selective, local activation of members of the tnf ligand family of systemically inactive non-antibody tnf ligand fusion proteins |
| 04/29/2004 | WO2004035779A1 Biomolecule transfer method using virus envelope and composition and system therefor |
| 04/29/2004 | WO2004035657A1 Process for the preparation of polyethylene glycol bis amine |
| 04/29/2004 | WO2004035629A2 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 04/29/2004 | WO2004035537A2 Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
| 04/29/2004 | WO2004035536A2 Azo compounds for type i phototherapy |
| 04/29/2004 | WO2004035523A1 Cationic cardiolipin analogs and use thereof |
| 04/29/2004 | WO2004035096A1 Composition exhibiting stabilised oxidation-reduction properties and method for the stabilisation thereof |